bimatoprost · Abbvie · NDA 211911
Durysta
Earliest generic entry, as listed
31 Oct 2034
Blocked by patent: US 9492316, US 9980974.
Listed patents · 7 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 9492316 | drug product · sets the listed date | 31 Oct 2034 |
| US 9980974 | use U-2759 · sets the listed date | 31 Oct 2034 |
| US 8629185 | drug substance, drug product | 15 Jul 2031 |
| US 7799336 | drug product | 24 Apr 2029 |
| US 8206737 | use U-2759 | 7 Apr 2027 |
| US 10441543 | drug product | 19 Dec 2026 |
| US 9149428 | drug product | 19 Dec 2026 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 211911 · 001 · RLD | implant, ophthalmic | 10MCG | 31 Oct 2034 |